We are live on ! Find out more
HAE icon

Haemonetics

192 hedge funds and large institutions have $1.78B invested in Haemonetics in 2014 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 66 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 34

0% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 66

2% less funds holding

Funds holding: 195192 (-3)

1.6% less ownership

Funds ownership: 107.02%105.42% (-1.6%)

23% less capital invested

Capital invested by funds: $2.32B → $1.78B (-$540M)

70% less call options, than puts

Call options by funds: $411K | Put options by funds: $1.38M

Holders
192
Holders Change
-3
Holders Change %
-1.54%
% of All Funds
5.55%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
34
Increased
66
Reduced
66
Closed
34
Calls
$411K
Puts
$1.38M
Net Calls
-$968K
Net Calls Change
-$968K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
26
American Capital Management
New York
$23.4M -$707K -18,490 -3%
KCM
27
Kornitzer Capital Management
Kansas
$23.1M -$21.6M -565,481 -44%
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$22.7M +$1.37M +35,740 +5%
Macquarie Group
29
Macquarie Group
Australia
$22.2M -$5.95M -155,812 -19%
Wells Fargo
30
Wells Fargo
California
$20.7M -$11.2M -292,256 -32%
EIP
31
Epoch Investment Partners
New York
$17.9M +$714K +18,670 +4%
USAA
32
United Services Automobile Association
Texas
$17.5M +$8.35M +218,500 +68%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$17.3M -$9.75M -255,076 -32%
PIM
34
Perkins Investment Management
Illinois
$15M +$17.6M +460,389 New
KIM
35
Kestrel Investment Management
California
$14.4M -$426K -11,150 -2%
Nordea Investment Management
36
Nordea Investment Management
Sweden
$13.9M -$922K -24,132 -5%
MTB
37
Mizuho Trust & Banking
Japan
$13.6M -$353K -9,247 -2%
CIP
38
Chartwell Investment Partners
Pennsylvania
$12.7M -$298K -7,805 -2%
Norges Bank
39
Norges Bank
Norway
$12.1M
SAM
40
Sentinel Asset Management
Vermont
$11.9M +$59.2K +1,550 +0.4%
Principal Financial Group
41
Principal Financial Group
Iowa
$10.8M +$523K +13,696 +4%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$9.66M
Geode Capital Management
43
Geode Capital Management
Massachusetts
$9.03M +$875K +22,885 +9%
KCM
44
Kennedy Capital Management
Missouri
$8.86M -$207K -5,416 -2%
Schroder Investment Management Group
45
Schroder Investment Management Group
United Kingdom
$8.39M +$126K +3,300 +1%
Renaissance Technologies
46
Renaissance Technologies
New York
$8.29M +$8.72M +228,126 +874%
MAA
47
Managed Account Advisors
New Jersey
$7.89M +$67.8K +1,773 +0.7%
Citadel Advisors
48
Citadel Advisors
Florida
$7.63M +$8.95M +234,262 New
RFC
49
Russell Frank Company
Washington
$7.51M +$2.2M +57,629 +33%
Two Sigma Investments
50
Two Sigma Investments
New York
$7.14M +$7.99M +209,015 +2,055%

HAE Hedge Fund Activity: Q1 2014 in Review

192 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2014, worth a combined $1.78B — down 23% from $2.32B a quarter earlier.

Fund positioning in HAE was balanced in Q1 2014: 34 funds opened new positions, 34 closed out, 66 added to existing stakes and 66 trimmed.

The largest buyer was Barrow, Hanley, Mewhinney & Strauss, adding an estimated $79.7M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $106M sold.

  • 192 institutional investors held Haemonetics (HAE) as of Q1 2014, down from 195 in Q4 2013.
  • Funds reported $1.78B of Haemonetics stock for Q1 2014, down 23% quarter-over-quarter.
  • 34 funds opened new Haemonetics positions in Q1 2014 and 34 closed out, a net change of 0 holders.
  • The largest Haemonetics buyer in Q1 2014 was Barrow, Hanley, Mewhinney & Strauss, an estimated $79.7M added.
  • The largest Haemonetics seller in Q1 2014 was TimesSquare Capital Management, an estimated $106M sold.

Based on aggregated 13F filings for Q1 2014.